Subjects must meet all the following inclusion criteria to be eligible:

          1. Subjects must have a histologically-confirmed malignancy that is metastatic or
             unresectable for which there is no remaining standard therapy known to confer clinical
             benefit. While all solid tumor types are eligible for the study, there is a preference
             to enroll patients with colorectal cancer, squamous cell carcinoma of the head and
             neck, urothelial cancer, endometrial cancer, NSCLC, and gastric or gastroesophageal
             junction adenocarcinoma.

          2. Subjects must have a tumor that is at least 1 cm in a single dimension and is
             radiographically apparent on CT or MRI.

          3. Eastern Cooperative Oncology Group performance status of 0 or 1 at treatment
             initiation.

          4. Life expectancy estimated to be ≥ 12 weeks

          5. Adequate organ and marrow function (subjects must not have received transfusions or
             growth factor support within 1 month prior to first dose of investigational product)
             as defined below:

               -  Albumin ≥ 3.0 g/dL

               -  Hemoglobin ≥ 10.0 g/dL

               -  Absolute neutrophil count ≥ 1,000/mm3

               -  Platelet count ≥ 100,000/mm3

               -  Bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); for subjects with
                  documented/suspected Gilbert's disease, bilirubin should be ≤ 2 × ULN.

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × ULN; for
                  subjects with liver metastases, AST or ALT ≤ 5 × ULN

               -  Creatinine ≤ 1.5×ULN OR calculated creatinine clearance (CrCl) ≥ 60 mL/min for
                  subjects with creatinine levels > 1.5× ULN.

        Subjects who meet any of the following exclusion criteria will not be eligible to receive
        investigational product:

          1. Concurrent enrollment in another clinical study, unless it is an observational (non
             interventional) clinical study, a specimen-collection study or the follow-up period of
             an interventional study.

          2. Received more than 4 doses of nonsteroidal anti-inflammatory drugs or COX-2 inhibitors
             within 2 weeks prior to study treatment initiation.

          3. History of allergy or hypersensitivity, GI bleed, or ulceration secondary to
             nonsteroidal anti-inflammatory drugs or COX-2 inhibitors.

          4. History of GI ulcer within 1 year of treatment initiation or history of untreated
             helicobacter pylori infection. Subjects with history of treated helicobacter pylori
             infection with confirmation of eradication are eligible

          5. History of diverticulitis or any GI bleed within 2 years of treatment initiation.

          6. Receipt of any anticancer therapy within the following windows:

               -  Small molecule tyrosine kinase inhibitor (TKI) therapy (including
                  investigational) within 2 weeks or 5 half-lives prior to treatment initiation,
                  whichever is longer

               -  Any type of anti-cancer antibody or cytotoxic chemotherapy within 4 weeks prior
                  to treatment initiation

               -  Radiation therapy for bone metastasis within 2 weeks, any other external
                  radiation therapy within 4 weeks before treatment initiation. Patients with
                  clinically relevant ongoing complications from prior radiation therapy are not
                  eligible

               -  Other investigational therapy within 2 weeks or 5 half-lives prior to dosing,
                  whichever is longer

          7. Subjects with active or untreated central nervous system (CNS) metastases

          8. New York Heart Association Classification II, III or IV.

          9. Baseline QTcF > 470 milliseconds

         10. Receipt of live attenuated vaccines within 30 days prior to the first dose of
             investigational product. (Killed virus or other non-live vaccines are allowed
             (including most seasonal influenza vaccines, streptococcus pneumonia vaccines, and
             newly approved COVID-19 vaccines).

         11. Active autoimmune disease or inflammatory disorders including inflammatory bowel
             disease (e.g., ulcerative colitis or Crohn's disease) requiring systemic treatment
             (i.e., with use of disease modifying agents, systemic corticosteroids or
             immunosuppressive drug) within 2 years prior to treatment initiation.

         12. Known human immunodeficiency virus (HIV) infection, active Hepatitis B (HBV), or
             hepatitis C (HCV). Active HBV is defined as a known positive HBsAg result. Active HCV
             is defined by a known positive HCV antibody result and known quantitative HCV RNA
             results greater than the lower limits of detection of the assay. Patients receiving
             antiviral therapy for Hepatitis B or C also are not eligible

         13. Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, serious chronic gastrointestinal conditions
             associated with diarrhea, or psychiatric illness/social situations including a history
             of substance abuse that would limit compliance with study requirement, substantially
             increase risk of incurring AEs or compromise the ability of the patient to give
             written informed consent.

         14. Subjects who are receiving anti-coagulant therapy or who are considered to be at
             increased risk of bleeding (i.e bleeding disorder or coagulopathy).

         15. Administration of the following substrates for drug transporters OATP1B1 and OATP1B3
             is prohibited while on study or within 7 days of treatment initiation: glyburide,
             digoxin, docetaxel, paclitaxel, pitavastatin, rosuvastatin, simvastatin or saquinavir